These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6460010)

  • 1. Systematic discovery and evaluation of complement inhibitors.
    Bauman N; Brockman JA; Pease BS; Elliott WJ; Colucci DF
    Immunopharmacology; 1981 Dec; 3(4):317-24. PubMed ID: 6460010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor.
    Hitomi Y; Fujii S
    Int Arch Allergy Appl Immunol; 1982; 69(3):262-7. PubMed ID: 6215361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Arthus reaction in rodents: species-specific requirement of complement.
    Szalai AJ; Digerness SB; Agrawal A; Kearney JF; Bucy RP; Niwas S; Kilpatrick JM; Babu YS; Volanakis JE
    J Immunol; 2000 Jan; 164(1):463-8. PubMed ID: 10605043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-selectin requirement for neutrophil accumulation and injury in the direct passive Arthus reaction.
    Santos LL; Huang XR; Berndt MC; Holdsworth SR
    Clin Exp Immunol; 1998 May; 112(2):281-6. PubMed ID: 9649192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific inactivation of the fourth complement component. I. In vivo studies.
    Jensen JA; Garces MC; Iglesias E
    Infect Immun; 1971 Jul; 4(1):12-9. PubMed ID: 4263696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of fumaropimaric acid in guinea pig complement dependent and non-complement dependent biologic reactions. I. Inhibition of Forssman, reversed passive arthus, and PCA reactions by fumaropimaric acid.
    Glovsky MM; Ward PA; Becker EL; Halbrook NJ
    J Immunol; 1969 Jan; 102(1):1-14. PubMed ID: 4237108
    [No Abstract]   [Full Text] [Related]  

  • 7. Complement inhibition by amidines and guanidines--in vivo and in vitro results.
    Otterness IG; Torchia AJ; Doshan HD
    Biochem Pharmacol; 1978; 27(14):1873-8. PubMed ID: 708469
    [No Abstract]   [Full Text] [Related]  

  • 8. The Forssman skin test and the Arthus reaction.
    Spear GS; Kihara I; Hertzog RW
    J Reticuloendothel Soc; 1973 Feb; 13(2):143-54. PubMed ID: 4267517
    [No Abstract]   [Full Text] [Related]  

  • 9. [Homeostasis of the complement system--complement inhibitors].
    Nagaki K
    Nihon Rinsho; 1979 May; 37(5):969-76. PubMed ID: 381728
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anti-allergic effects of (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046), a specific thromboxane (TX) A2 synthetase inhibitor: effect of OKY-046 on II-IV type allergic reactions].
    Kikuchi S; Takehana Y; Hamano S; Ichikawa K; Komatsu H; Okegawa T; Ikeda S
    Nihon Yakurigaku Zasshi; 1990 Mar; 95(3):131-7. PubMed ID: 2141317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice.
    Inal JM; Schneider B; Armanini M; Schifferli JA
    J Immunol; 2003 Apr; 170(8):4310-7. PubMed ID: 12682267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunopharmacologic and anti-inflammatory properties of RMI 9563 with special reference to its effect on the complement system.
    Megel H; Raychaudhuri A; Bayer M; Beaver TH
    Agents Actions; 1978 Apr; 8(3):218-28. PubMed ID: 149492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of newly synthesized active center-directed trypsin-like serine protease inhibitors on the complement system.
    Ueda N; Midorikawa A; Ino Y; Oda M; Nakamura K; Suzuki S; Kurumi M
    Inflamm Res; 2000 Jan; 49(1):42-6. PubMed ID: 10778920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
    Aoyama T; Ino Y; Ozeki M; Oda M; Sato T; Koshiyama Y; Suzuki S; Fujita M
    Jpn J Pharmacol; 1984 Jul; 35(3):203-27. PubMed ID: 6482087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntheses and complement inhibitory activities of 4-(2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acids.
    Bailey DM; DeGrazia GD; Alexander EJ; Powles RG; Johnson RE; Patrick RA; Heerdt BG; Fairbain ME; Pruden DJ
    J Med Chem; 1985 Feb; 28(2):160-4. PubMed ID: 3155799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate (FUT-187). I: Inhibitory activities on various kinds of enzymes in vitro and anticomplement activity in vivo.
    Oda M; Ino Y; Nakamura K; Kuramoto S; Shimamura K; Iwaki M; Fujii S
    Jpn J Pharmacol; 1990 Jan; 52(1):23-34. PubMed ID: 1689782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
    Basta M; Kirshbom P; Frank MM; Fries LF
    J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
    Butler KD; White AM
    Artery; 1980; 8(5):457-69. PubMed ID: 6452106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
    Houle JJ; Hoffmann EM
    J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1.
    Tenner AJ; Frank MM
    J Immunol; 1986 Jul; 137(2):625-30. PubMed ID: 3722818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.